{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:06:43Z","timestamp":1791385603103,"version":"4.3.3"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006765","name":"Chinese Medical Association","doi-asserted-by":"publisher","award":["1430310568"],"award-info":[{"award-number":["1430310568"]}],"id":[{"id":"10.13039\/501100006765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.03.011","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T09:19:08Z","timestamp":1618564748000},"page":"238-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China"],"prefix":"10.1016","volume":"25","author":[{"given":"Fangyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.03.011_bib0001","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jgar.2021.03.011_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/viru.26187","article-title":"Invasive candidiasis as a cause of sepsis in the critically ill patient","volume":"5","author":"Delaloye","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.jgar.2021.03.011_bib0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/mmy\/myx066","article-title":"Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia Fungal Working Group (AFWG) initiative","volume":"56","author":"Chindamporn","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.jgar.2021.03.011_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11684-017-0601-0","article-title":"Epidemiology of fungal infections in China","volume":"12","author":"Chen","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jgar.2021.03.011_bib0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0006","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","article-title":"ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients","volume":"45","author":"Martin-Loeches","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2021.03.011_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0008","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"W\u00fcrthwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0009","doi-asserted-by":"crossref","first-page":"e01582","DOI":"10.1128\/AAC.01582-16","article-title":"Low caspofungin exposure in patients in intensive care units","volume":"61","author":"van der Elst","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0010","doi-asserted-by":"crossref","first-page":"e02466","DOI":"10.1128\/AAC.02466-18","article-title":"Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels","volume":"63","author":"Kurland","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0011","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijantimicag.2017.05.013","article-title":"Dosing of caspofungin based on a pharmacokinetic\/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration","volume":"51","author":"P\u00e9rez-Pitarch","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.03.011_bib0012","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0013","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0014","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01490-12","article-title":"Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths","volume":"57","author":"Hall","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijantimicag.2016.02.004","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations","volume":"47","author":"Yang","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.03.011_bib0016","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","article-title":"Medical Mycology Study Group (GEMICOMED) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC); Spanish Network for Research in Infectious Diseases. Impact of therapeutic strategies on the prognosis of candidemia in the ICU","volume":"42","author":"Puig-Asensio","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.03.011_bib0017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciu158","article-title":"Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis","volume":"58","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0018","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/jac\/dkw305","article-title":"Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12)","volume":"71","author":"Chiotos","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0019","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1093\/jac\/dku313","article-title":"Pharmacokinetics of caspofungin in ICU patients","volume":"69","author":"Muilwijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bcp.13404","article-title":"Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials","volume":"84","author":"Patel","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.03.011_bib0021","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jcph.849","article-title":"Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase","volume":"57","author":"Hong","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.03.011_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.03.011_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/clpt.2012.221","article-title":"Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism","volume":"94","author":"Tomita","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2021.03.011_bib0024","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/dmd.104.003244","article-title":"Hepatic uptake of the novel antifungal agent caspofungin","volume":"33","author":"Sandhu","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jgar.2021.03.011_bib0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2174\/1381612821666150302113710","article-title":"Studies on drug\u2013human serum albumin binding: the current state of the matter","volume":"21","author":"Zhivkova","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jgar.2021.03.011_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2021.03.011_bib0027","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.03.011_bib0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkm125","article-title":"Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit","volume":"60","author":"Nguyen","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/15216540500404093","article-title":"The extraordinary ligand binding properties of human serum albumin","volume":"57","author":"Fasano","year":"2005","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jgar.2021.03.011_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1053\/j.ajkd.2007.12.035","article-title":"A review of albumin binding in CKD","volume":"51","author":"Meijers","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0031","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.13245","article-title":"Cefoperazone\/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: potential factors affecting the pharmacokinetic\/pharmacodynamic target attainment","volume":"125","author":"Dong","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jgar.2021.03.011_bib0032","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00134-009-1511-7","article-title":"Liver function tests\u2019 on the intensive care unit: a prospective, observational study","volume":"35","author":"Thomson","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2021.03.011_bib0033","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.chest.2017.08.018","article-title":"Cholestatic alterations in the critically ill: some new light on an old problem","volume":"153","author":"Jenniskens","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2021.03.011_bib0034","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.mehy.2013.07.013","article-title":"Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues\u2014a rationale for the versatile health protection associated with elevated plasma bilirubin","volume":"81","author":"McCarty","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jgar.2021.03.011_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/jsre.2000.6036","article-title":"Increased urinary excretion of bilirubin oxidative metabolites in septic patients: a new marker for oxidative stress in vivo","volume":"96","author":"Otani","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.jgar.2021.03.011_bib0036","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.CCM.0000259462.97164.A0","article-title":"Austrian Epidemiologic Study on Intensive Care, ASDI Study Group. Incidence and prognosis of early hepatic dysfunction in critically ill patients\u2014a prospective multicenter study","volume":"35","author":"Kramer","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.03.011_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3476(59)80223-7","article-title":"The dissociation of bilirubin from albumin and its clinical implications","volume":"55","author":"Odell","year":"1959","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.03.011_bib0038","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/clinids\/5-Supplement_1.S127","article-title":"Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function","volume":"5","author":"Greenfield","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0039","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2021.03.011_bib0040","series-title":"Cancidas EPAR product information","year":"2019"},{"key":"10.1016\/j.jgar.2021.03.011_bib0041","series-title":"Cancidas FDA label information","year":"2019"},{"key":"10.1016\/j.jgar.2021.03.011_bib0042","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijantimicag.2015.08.009","article-title":"Assessment of echinocandin regimens by pharmacokinetic\/pharmacodynamic analysis against Candida spp. in paediatric patients","volume":"46","author":"Xu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.03.011_bib0043","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkt330","article-title":"China-SCAN Team. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study","volume":"69","author":"Liu","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0044","doi-asserted-by":"crossref","first-page":"e02045","DOI":"10.1128\/AAC.02045-16","article-title":"Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.011_bib0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2020.09.019","article-title":"Pharmacokinetics of echinocandins in suspected Candida peritonitis: a potential risk for resistance","volume":"101","author":"Gioia","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.011_bib0046","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652100076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652100076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:11Z","timestamp":1761990911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652100076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":46,"alternative-id":["S221371652100076X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}